Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator
- I. Y. Sazonova,
- R. A. McNamee,
- A. K. Houng,
- S. M. King,
- L. Hedstrom,
- Guy L. Reed(corresponding author)
- ,
- ,
- University of Tennessee Health Science Center,
- Augusta University,
- Brandeis University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Background: Given the worldwide epidemic of cardiovascular diseases, a more effective means of dissolving thrombi that cause heart attacks, could markedly reduce death, disability and healthcare costs. Plasminogen activators (PAs) such as streptokinase (SK) and tissue plasminogen activator (TPA) are currently used to dissolve fibrin thrombi. SK is cheaper and more widely available, but it appears less effective because it lacks TPA's fibrin-targeted properties that focus plasminogen activation on the fibrin surface. Objective: We examined whether re-programming SK's mechanism of action would create PAs with greater fibrin-targeting and potency than TPA. Methods and Results: When fibrinogen consumption was measured in human plasma, reprogrammed molecules SKΔ1 and SK Δ 59 were 5-fold and > 119-fold more fibrin-dependent than SK (P < 0.0001), and 2-fold and > 50-fold more fibrin-dependent than TPA (P < 0.001). The marked fibrin-targeting of SKΔ59 was due to the fact that: (i) it did not generate plasmin in plasma, (ii) it was rapidly inhibited by α2-antiplasmin, and (iii) it only processed fibrin-bound plasminogen. To assess the fibrin-targeting and therapeutic potential of these PAs in vivo, a novel 'humanized' fibrinolysis model was created by reconstituting plasminogen-deficient mice with human plasminogen. When compared with TPA, SKΔ1 and SKΔ59 were 4-fold (P < 0.0001) and 2-fold (P < 0.003) more potent at dissolving blood clots in vivo, respectively, on a mass-dose basis and 2-3 logs more potent than TPA (P < 0.0001) when doses were calibrated by standard activity assays. Conclusion: These experiments suggest that reprogramming SK's mechanism of action markedly enhances fibrin-targeting and creates, in comparison with TPA, activators with greater fibrinolytic potency.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1321-1328 (8 pages)Journal (Volume, Issue Number)
Journal of Thrombosis and Haemostasis (Volume 7, Issue 8)Publication milestones
- Published - 2009
Publication status
Published - 2009
ISSN
1538-7933Publication IDs
- Scopus: 67949118895
- PubMed: 19566545
Publication metrics
Metrics
SciVal
citations
14
SciVal
FWCI
0.54
SciVal
Author count
6
SciVal
Paper percentile
68
Fractional count
2
Fractional count
0.33
Fractional count
4
Fractional count
0.67
Fractional count
2
Fractional count
1
PlumX, opens in new tab
Social media
3
Captures
10
Citation count
15
Funding Details
FunderFunding number
NHLBI
R01HL058496
